25 de marzo de 2019
  • Domingo, 24 de Marzo
  • Sábado, 23 de Marzo
  • 16 de abril de 2010

    New Data Supporting Cladribine Tablets as a Potential New Therapeutic Option Presented at the 62nd AAN Annual Meeting (y

    The clinical development program for Cladribine Tablets includes:
    - The CLARITY (CLAdRIbine Tablets Treating MS OrallY) study and its
    extension: a two-year Phase III placebo-controlled trial designed to
    evaluate the efficacy and safety of Cladribine Tablets as a monotherapy
    in patients with relapsing-remitting MS and its two-year extension
    designed to provide data on the long-term safety and efficacy of
    extended administration of Cladribine Tablets for up to four years.
    - The ORACLE MS (ORAl CLadribine in Early MS) study: a two-year
    Phase III placebo-controlled trial designed to evaluate the efficacy
    and safety of Cladribine Tablets as a monotherapy in patients at risk
    of developing MS (patients who have experienced a first clinical event
    suggestive of MS). This trial was announced in September 2008.
    - The ONWARD (Oral Cladribine Added ON To Interferon beta-1a in Patients
    With Active Relapsing Disease) study: a Phase II placebo-controlled
    trial designed primarily to evaluate the safety and tolerability of
    adding Cladribine Tablets treatment to patients with relapsing forms
    of MS, who have experienced breakthrough disease while on established
    interferon-beta therapy. This trial was announced in January 2007.

    About multiple sclerosis

    Multiple sclerosis (MS) is a chronic, inflammatory condition of the central nervous system and is the most common, non-traumatic, disabling neurological disease in young adults. It is estimated that more than two million people have MS worldwide. While symptoms can vary, the most common symptoms of MS include blurred vision, numbness or tingling in the limbs and problems with strength and coordination. The relapsing forms of MS are the most common.

    About Merck Serono

    Merck Serono is the division for innovative prescription pharmaceuticals of Merck KGaA, Darmstadt, Germany, a global pharmaceutical and chemical company. Headquartered in Geneva, Switzerland, Merck Serono discovers, develops, manufactures and markets innovative small molecules and biopharmaceuticals to help patients with unmet medical needs. In the United States and Canada, EMD Serono operates through separately incorporated affiliates.

    Merck Serono has leading brands serving patients with cancer (Erbitux(R), cetuximab), multiple sclerosis (Rebif(R), interferon beta-1a), infertility (Gonal-f(R), follitropin alpha), endocrine and metabolic disorders (Saizen(R) and Serostim(R), somatropin), (Kuvan(R), sapropterin dihydrochloride) as well as cardiometabolic diseases (Glucophage(R), metformin), (Concor(R), bisoprolol), (Euthyrox(R), levothyroxine). Not all products are available in all markets.

    With an annual R&D expenditure of more than EUR 1bn, Merck Serono is committed to growing its business in specialist-focused therapeutic areas including neurodegenerative diseases, oncology, fertility and endocrinology, as well as new areas potentially arising out of research and development in autoimmune and inflammatory diseases.

    About Merck

    Merck is a global pharmaceutical and chemical company with total revenues of EUR 7.7 billion in 2009, a history that began in 1668, and a future shaped by approximately 33,000 employees in 61 countries. Its success is characterized by innovations from entrepreneurial employees. Merck's operating activities come under the umbrella of Merck KGaA, in which the Merck family holds an approximately 70% interest and free shareholders own the remaining approximately 30%. In 1917 the U.S. subsidiary Merck & Co. was expropriated and has been an independent company ever since.

    For more information, please visit http://www.merckserono.com or http://www.merck.de

    Media Relations: Tel.: +41-22-414-36-00